Key Trial Findings
-
Favourable safety profile of eftilagimod alpha in combination with pembrolizumab
-
Deep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in part A and B respectively
-
Disease Control Rate of 66% of patients in each Part A and B (24 patients in total)
SYDNEY, AUSTRALIA – October 15, 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase I clinical study combining its lead product candidate, eftilagimod alpha (“efti” or “IMP321”) with KEYTRUDA® (pembrolizumab) in metastatic melanoma.
For further information please download the attached PDF:
Download this document
